[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"unspecified-adult-solid-tumor-protocol-specific\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:unspecified-adult-solid-tumor-protocol-specific":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,201,228,248,284,305],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":200},"100143410","registry-of-older-patients-with-cancer-100143410",false,"NCT01137825","Registry of Older Patients With Cancer","Carolina Senior: UNC Registry for Older Cancer Patients","DISEASE CHARACTERISTICS:\n\n* Patients must have an appointment at the North Carolina Cancer Hospital and agree to complete the Geriatric Assessment NOTE: Not all patients included in the registry will ultimately be diagnosed with cancer. Patients who complete a GA and are not diagnosed with cancer will remain in the database, but will be categorized into a separate group and will not have their medical records accessed.\n\nPATIENT CHARACTERISTICS:\n\n* Able to read and speak English\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","ALL","65 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future.\n\nPURPOSE: This research study is gathering information from older patients with cancer into a registry.",[24,25,26,27,28,29,30,31,32],"Chronic Myeloproliferative Disorders","Cognitive\u002FFunctional Effects","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms","Unspecified Adult Solid Tumor, Protocol Specific",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187],"cognitive\u002Ffunctional effects","unspecified adult solid tumor, protocol specific","accelerated phase chronic myelogenous leukemia","acute undifferentiated leukemia","adult acute lymphoblastic leukemia in remission","adult acute myeloid leukemia in remission","adult acute myeloid leukemia with 11q23 (MLL) abnormalities","adult acute myeloid leukemia with inv(16)(p13;q22)","adult acute myeloid leukemia with t(15;17)(q22;q12)","adult acute myeloid leukemia with t(16;16)(p13;q22)","adult acute myeloid leukemia with t(8;21)(q22;q22)","atypical chronic myeloid leukemia, BCR-ABL negative","blastic phase chronic myelogenous leukemia","chronic myelomonocytic leukemia","chronic phase chronic myelogenous leukemia","mast cell leukemia","meningeal chronic myelogenous leukemia","progressive hairy cell leukemia, initial treatment","prolymphocytic leukemia","recurrent adult acute lymphoblastic leukemia","recurrent adult acute myeloid leukemia","recurrent adult T-cell leukemia\u002Flymphoma","refractory chronic lymphocytic leukemia","refractory hairy cell leukemia","relapsing chronic myelogenous leukemia","secondary acute myeloid leukemia","stage 0 chronic lymphocytic leukemia","stage I adult T-cell leukemia\u002Flymphoma","stage I chronic lymphocytic leukemia","stage II adult T-cell leukemia\u002Flymphoma","stage II chronic lymphocytic leukemia","stage III adult T-cell leukemia\u002Flymphoma","stage III chronic lymphocytic leukemia","stage IV adult T-cell leukemia\u002Flymphoma","stage IV chronic lymphocytic leukemia","T-cell large granular lymphocyte leukemia","untreated adult acute lymphoblastic leukemia","untreated adult acute myeloid leukemia","untreated hairy cell leukemia","recurrent adult Hodgkin lymphoma","stage I adult Hodgkin lymphoma","stage II adult Hodgkin lymphoma","stage III adult Hodgkin lymphoma","stage IV adult Hodgkin lymphoma","anaplastic large cell lymphoma","angioimmunoblastic T-cell lymphoma","cutaneous B-cell non-Hodgkin lymphoma","recurrent cutaneous T-cell non-Hodgkin lymphoma","stage I cutaneous T-cell non-Hodgkin lymphoma","stage II cutaneous T-cell non-Hodgkin lymphoma","stage III cutaneous T-cell non-Hodgkin lymphoma","stage IV cutaneous T-cell non-Hodgkin lymphoma","recurrent mycosis fungoides\u002FSezary syndrome","stage I mycosis fungoides\u002FSezary syndrome","stage II mycosis fungoides\u002FSezary syndrome","stage III mycosis fungoides\u002FSezary syndrome","stage IV mycosis fungoides\u002FSezary syndrome","adult grade III lymphomatoid granulomatosis","adult nasal type extranodal NK\u002FT-cell lymphoma","Waldenstrom macroglobulinemia","extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","nodal marginal zone B-cell lymphoma","splenic marginal zone lymphoma","contiguous stage II adult Burkitt lymphoma","contiguous stage II adult diffuse large cell lymphoma","contiguous stage II adult diffuse mixed cell lymphoma","contiguous stage II adult diffuse small cleaved cell lymphoma","contiguous stage II adult immunoblastic large cell lymphoma","contiguous stage II adult lymphoblastic lymphoma","contiguous stage II grade 1 follicular lymphoma","contiguous stage II grade 2 follicular lymphoma","contiguous stage II grade 3 follicular lymphoma","contiguous stage II mantle cell lymphoma","contiguous stage II marginal zone lymphoma","contiguous stage II small lymphocytic lymphoma","stage I adult Burkitt lymphoma","stage I adult diffuse large cell lymphoma","stage I adult diffuse mixed cell lymphoma","stage I adult diffuse small cleaved cell lymphoma","stage I adult immunoblastic large cell lymphoma","stage I adult lymphoblastic lymphoma","stage I grade 1 follicular lymphoma","stage I grade 2 follicular lymphoma","stage I grade 3 follicular lymphoma","stage I mantle cell lymphoma","stage I marginal zone lymphoma","stage I small lymphocytic lymphoma","noncontiguous stage II adult Burkitt lymphoma","noncontiguous stage II adult diffuse large cell lymphoma","noncontiguous stage II adult diffuse mixed cell lymphoma","noncontiguous stage II adult diffuse small cleaved cell lymphoma","noncontiguous stage II adult immunoblastic large cell lymphoma","noncontiguous stage II adult lymphoblastic lymphoma","noncontiguous stage II grade 1 follicular lymphoma","noncontiguous stage II grade 2 follicular lymphoma","noncontiguous stage II grade 3 follicular lymphoma","noncontiguous stage II mantle cell lymphoma","noncontiguous stage II marginal zone lymphoma","noncontiguous stage II small lymphocytic lymphoma","stage III adult Burkitt lymphoma","stage III adult diffuse large cell lymphoma","stage III adult diffuse mixed cell lymphoma","stage III adult diffuse small cleaved cell lymphoma","stage III adult immunoblastic large cell lymphoma","stage III adult lymphoblastic lymphoma","stage III grade 1 follicular lymphoma","stage III grade 2 follicular lymphoma","stage III grade 3 follicular lymphoma","stage III mantle cell lymphoma","stage III marginal zone lymphoma","stage III small lymphocytic lymphoma","stage IV adult Burkitt lymphoma","stage IV adult diffuse large cell lymphoma","stage IV adult diffuse mixed cell lymphoma","stage IV adult diffuse small cleaved cell lymphoma","stage IV adult immunoblastic large cell lymphoma","stage IV adult lymphoblastic lymphoma","stage IV grade 1 follicular lymphoma","stage IV grade 2 follicular lymphoma","stage IV grade 3 follicular lymphoma","stage IV mantle cell lymphoma","stage IV marginal zone lymphoma","stage IV small lymphocytic lymphoma","recurrent adult Burkitt lymphoma","recurrent adult diffuse large cell lymphoma","recurrent adult diffuse mixed cell lymphoma","recurrent adult diffuse small cleaved cell lymphoma","recurrent adult grade III lymphomatoid granulomatosis","recurrent adult immunoblastic large cell lymphoma","recurrent adult lymphoblastic lymphoma","recurrent grade 1 follicular lymphoma","recurrent grade 2 follicular lymphoma","recurrent grade 3 follicular lymphoma","recurrent mantle cell lymphoma","recurrent marginal zone lymphoma","recurrent small lymphocytic lymphoma","intraocular lymphoma","post-transplant lymphoproliferative disorder","chronic eosinophilic leukemia","chronic neutrophilic leukemia","primary myelofibrosis","essential thrombocythemia","polycythemia vera","extramedullary plasmacytoma","isolated plasmacytoma of bone","stage I multiple myeloma","stage II multiple myeloma","stage III multiple myeloma","primary systemic amyloidosis","refractory multiple myeloma","de novo myelodysplastic syndromes","previously treated myelodysplastic syndromes","secondary myelodysplastic syndromes","myelodysplastic\u002Fmyeloproliferative neoplasm, unclassifiable","RECRUITING","2026-06-24",{"date":191,"type":192},"2026-06-29","ACTUAL",{"date":194,"type":4},"2009-09",{"date":196,"type":20},"2030-12",{"name":198,"class":199},"UNC Lineberger Comprehensive Cancer Center","OTHER",7,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":212,"studyType":21,"phases":4,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100125420","collection-and-storage-of-tissue-samples-from-patients-undergoing-surgery-for-suspected-solid-tumors-100125420","NCT00900471","Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors","Advanced Tumor Bank Project","Inclusion Criteria:\n\n* Signed protocol specific informed consent prior to registration\u002Frandomization.\n* Clinically suspected solid tumor AND scheduled for surgical resection and\u002For biopsy","18 Years","120 Years",{"count":211,"type":20},20000,"1 Day","RATIONALE: Collecting and storing samples of tissue or blood from patients with cancer for study in the laboratory may help the study of cancer in the future\n\nPURPOSE: This research study is collecting and storing blood and tissue samples from patients with suspected solid tumors.",[32,215],"Unspecified Childhood Solid Tumor, Protocol Specific",[35,217],"unspecified childhood solid tumor, protocol specific","2026-03-16",{"date":220,"type":192},"2026-03-19",{"date":222,"type":192},"2004-04-01",{"date":224,"type":20},"2027-05",{"name":226,"class":199},"Wake Forest University Health Sciences",1,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":227},"100225709","genomic-profiling-in-recommending-treatment-for-patients-with-metastatic-solid-tumors-100225709","NCT02215928","Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors","Tumor Genomic Profiling: A Personalized Medicine Approach","Inclusion Criteria:\n\n* Understand and provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization prior to initiation of any study-specific procedures\n* Have a diagnosis of metastatic, incurable cancer and have progressed on at least one line of systemic therapy OR a cancer with no standard 1st-line systemic therapy shown to prolong survival (or where a clinical trial recommended as the 1st-line option)\n* Measurable disease (RECIST 1.1)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* In the opinion of the investigator, be medically suitable for and willing to undergo a biopsy or surgical procedure to obtain tissue as a part of routine care for their malignancy OR have adequate archival tissue from a previous biopsy available for profiling\n* Female patients of childbearing potential must have a negative pregnancy test and agree to use at least one form of contraception during the study and for at least one month after treatment discontinuation; for the purposes of this study, child-bearing potential is defined as: all female patients that were not in post-menopause for at least one year or are surgically sterile\n* Male patients must use a form of barrier contraception approved by the investigator\u002Ftreating physician during the study and for at least one month after treatment discontinuation\n\nExclusion Criteria:\n\n* Have lesions that are not accessible to biopsy or not planned for biopsy as part of routine care OR if archival tissue will be used for profiling, an insufficient amount is available\n* Have diagnosis of a hematologic malignancy\n* Have symptomatic central nervous system (CNS) metastasis; patients with a history of CNS metastases who have been treated with whole brain irradiation must be stable without symptoms for 4 weeks after completion of treatment, with image documentation required, and must be either off steroids or on a stable dose of steroids for \\>= 2 weeks prior to enrollment\n* Have uncontrolled concurrent illness including, but not limited to, ongoing or active serious infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmias, psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent\n* Have known human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) infection\n* Are pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception",{"count":236,"type":20},100,"This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profiling studies the deoxyribonucleic acid (DNA) of a tumor to detect genetic changes or abnormalities. This information can then be used to recommend treatments that may be more likely to result in a beneficial response. It is not yet known whether genomic profiling will detect abnormalities that can be used to make treatment recommendations and whether treatment based on genomic profiling is more effective than standard treatment.",[32],"2025-12-17",{"date":241,"type":192},"2025-12-24",{"date":243,"type":192},"2014-07-28",{"date":245,"type":20},"2026-12",{"name":247,"class":199},"Stanford University",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":258,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":283},"100435774","phase-1-phase-12-clinical-trial-of-cp-506-hap-in-monotherapy-or-with-carboplatin-or-ici-100435774","NCT04954599","Phase 1\u002F2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","Phase 1\u002F2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD\u002FFAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI","Inclusion Criteria:\n\n1. Male or female, aged 18 years or more at the time of signing the informed consent\n2. Be willing and able to provide written informed consent for the trial\n3. Life expectancy of at least 3 months\n4. Be willing to have a biopsy collection procedure\n5. ECOG Performance status \\\u003C= 2\n6. Must have adequate organ and bone marrow function, defined as the following:\n\n   6.1. ANC ≥ 1500 µL 6.2. Hemoglobin ≥ 9.0 g\u002FdL 6.3. Platelets ≥ 100 000 µL 6.4. Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\>1.5 × ULN 6.5. AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases) 6.6. Creatinine ≤ 1.5 × ULN 6.7. Coagulation: INR ≤ 1.5 × ULN (or within therapeutic ranges for participants on anticoagulant treatment)\n7. Measurable disease on CT scan (RECIST 1.1)\n8. If female, not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n   8.1. Not a woman of childbearing potential (WOCBP) 8.2. A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 4 weeks after the last dose of study treatment and shows a negative pregnancy test before the start of the treatment\n9. If male, must agree to use contraception during the treatment period and for at least 4 weeks after the last dose of study treatment\n10. Able and willing to comply with the protocol Module 1 - monotherapy\n11. Have histologically or cytologically-confirmed advanced or metastatic solid tumour for whom no standard of care or known effective treatment options are available\n12. Have indications of Homologous Recombination (HR) or Fanconi Anaemia (FA) DNA damage repair defects, based on hereditary cancer diagnostics (e.g. BRCA1\u002F2 carriers), dedicated HRD genomic assays (including exome-sequencing) from liquid or tissue biopsies. Presence of such a defect must have been established via a tissue based next generation sequencing test, performed --in a CAP\u002FCLIAcertified (or comparable local or regional certification) laboratory, or via a germline test from one of the following approved providers: Myriad Genetics; Invitae; Ambry; Quest; Color Genomics; MSKCC-IMPACT; GeneDx; Foundation Medicine OR Have cancers with an increased incidence of HRD\u002FFAD: ovarian (41%), breast (18%), pancreas (10%), prostate (9%), and head and neck (5%) OR Patients who were previously responsive to alkylating agent (Partial Response\u002FComplete Response according to RECIST criteria).\n\n    Module 2 - Carboplatin combination\n13. Patient must be eligible to carboplatin treatment.\n14. Have histologically or cytologically-confirmed advanced or metastatic solid tumour for whom no standard of care or known effective treatment options are available.\n15. Receive carboplatin as standard of care: triple negative breast cancer or ovarian cancer.\n\n    Module 3 - ICI combination\n16. Have histologically or cytologically-confirmed advanced or metastatic solid tumour\n17. Receiving immune checkpoint inhibitor (ICI) monotherapy as standard of care for at least 6 months prior to the beginning of the study and who are oligoprogressive. Oligoprogression disease is defined as localized treatment failure at one or two anatomic sites, with one to five progressive and measurable (according to RECIST 1.1) lesions, either new or with ≥ 20% growth of their longest diameter (short-axis in lymph nodes), while other tumor manifestations could shrink or grow less than 20% in diameter\n\nExclusion Criteria:\n\nCore:\n\n1. Prior radiotherapy to more than 25% of bone marrow\n2. Not recovered from all acute toxic effects of prior anticancer therapy (excluding CTCAE Grade 1 alopecia or peripheral neuropathy)\n3. Patients with significant cardiac co-morbidity, such as NYHA Class III or IV CHF, unstable angina, MI within the previous 6 months, or ventricular arrhythmias requiring drug therapy, pacemaker or implanted defibrillator. Serious, uncontrolled cardiac arrhythmia or clinically significant electrocardiogram abnormalities including second degree (Type II) or third-degree atrioventricular block. This does not apply to patient with a pace maker. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting. Congestive heart failure (Class II, III, or IV) as defined by the New York Heart Association functional classification system. Symptomatic pericarditis\n4. A marked baseline prolongation of QT\u002FQTc interval (\\> 450 ms)\n5. History of risk factors for Torsade de Pointe (e.g. heart failure, hypokalemia, family history of Long QT syndrome)\n6. Use of concomitant medication prolonging the QT\u002FQTc interval\n7. Evidence of uncontrolled infection or infection requiring a concomitant parenteral antibiotic\n8. Evidence of any other significant clinical disorder or laboratory finding that in the opinion of the Investigator may compromise patient safety during study participation.\n9. Patients with a diagnosis (or strong suspicion) of a rare genetic disorder related to germline biallelic HR\u002FFA and DNA repair gene mutations, such as Fanconi anemia patients of any subtype, Ataxia telangiectasia, Xeroderma pigmentosum, Cockayne, Nijmegen breakage, Werner and Bloom syndrome patients\n10. Patient or physician plans concomitant chemotherapy, radiation therapy, hormonal and\u002For biological treatment for cancer including immunotherapy while on study\n11. Patient has been treated with any investigational drug or investigational therapeutic device within 30 days (60 days in case of biological compound) of initiating study treatment\n12. Less than 4 weeks since prior major surgery\n13. Known positive for HIV, Hepatitis B surface antigen positive or Hepatitis C positive with abnormal liver function tests\n14. Known allergy to alkylating agents\n15. Central nervous system (CNS) metastases, with the following exception:\n16. Participants with asymptomatic CNS metastases who are clinically stable and have no requirement for steroids for at least 14 days prior to randomization. Note: Participants with carcinomatous meningitis or leptomeningeal spread are excluded regardless of clinical stability\n17. Invasive malignancy or history of invasive malignancy other than disease under study within the last 3 years, except as noted below:\n\n    17.1. Any other invasive malignancy for which the participant was definitively treated, has been disease-free for ≤ 3 years and in the opinion of the principal investigator will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical study 17.2. Curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma 17.3. Low-risk early-stage prostate cancer defined as follows: Stage T1c or T2a with a Gleason score ≤ 6 and prostatic-specific antigen \\\u003C10 ng\u002FmL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to randomization\n18. Autoimmune disease (current or history; refer to Table 19) or syndrome that required systemic treatment within the past 2 years Note: Replacement therapies which include physiological doses of corticosteroids for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments\n19. Has a diagnosis of immunodeficiency or is receiving systemic steroids (\\>10 mg oral prednisone per day or equivalent) or other immunosuppressive agents within 7 days prior to randomization Note:\n\n    19.1. Physiologic doses of corticosteroids for treatment of endocrinopathies or steroids with minimal systemic absorption, including topical, inhaled, or intranasal corticosteroids may be continued if the participant is on a stable dose, up to a maximum of 10 mg prednisone per day or equivalent 19.2. Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \\[CT\\] scan premedication) are permitted.\n20. Receipt of any live vaccine within 30 days prior randomization\n21. Prior allogeneic\u002Fautologous bone marrow or solid organ transplantation\n22. Has current pneumonitis or history of non-infectious pneumonitis that required steroids or other immunosuppressive agents Note: post-radiation changes in the lung related to prior radiotherapy and\u002For asymptomatic radiation-induced pneumonitis not requiring treatment (Grade 1) may be permitted if agreed upon by the investigator and Medical Monitor.\n23. Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions\n24. Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intraabdominal abscess\n25. Recent history of allergen desensitization therapy within 4 weeks of randomization\n26. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice. Note: Stable non-cirrhotic, chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if participant otherwise meets entry criteria\n27. Known history of active tuberculosis\n28. Any psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator Module 1 - monotherapy\n29. Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion Module 2 - Carboplatin combination\n30. Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion with exclusion of carboplatin.\n\n    Module 3 - ICI combination\n31. Patients who have received anticancer therapy (including radiotherapy) within 4 weeks of inclusion with exception of ICI\n32. Patients progressive under ICI justifying the immediate discontinuation of ICI\n33. Patients who would not receive further treatment with ICI as standard of care\n34. Patients with Complete Response under ICI",{"count":256,"type":20},126,"INTERVENTIONAL",[259,260],"PHASE1","PHASE2","A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD\u002FFAD solid tumours or tumor types with high incidence of HRD\u002FFAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial",[32],[264,265,266,267,268,269,270,271,272,273,274],"Homologous recombination DNA repair defects","Fanconi Anaemia DNA repair defects","Triple negative breast cancer","Ovarian cancer","Prostate cancer","Pancreatic cancer","Head and neck cancer","Hypoxia Activated Prodrug","Alkylating Agents","Carboplatin","Immune Checkpoint Inhibitor","2025-10-02",{"date":277,"type":192},"2025-10-07",{"date":279,"type":192},"2023-05-30",{"date":224,"type":20},{"name":282,"class":199},"Maastricht University Medical Center",5,{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":4,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":303,"locationsCount":227},"100128032","3-deoxy-3-18f-fluorothymidine-pet-imaging-in-patients-with-cancer-100128032","NCT00935090","3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer","Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)","DISEASE CHARACTERISTICS:\n\n* Meets one of the following criteria:\n\n  * Histologically confirmed solid tumor or hematologic malignancy\n  * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging\n\nPATIENT CHARACTERISTICS:\n\n* Able to lie still in the PET scanner\n* Girth and weight must be suitable to enter the gantry\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* Not specified","RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\\[18F\\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.\n\nPURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.",[293,24,26,27,28,29,30,31,32],"Brain and Central Nervous System Tumors",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,295,296,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187],"primary central nervous system non-Hodgkin lymphoma","primary central nervous system Hodgkin lymphoma","2025-07-02",{"date":299,"type":192},"2025-07-08",{"date":194,"type":192},{"date":302,"type":20},"2028-05",{"name":304,"class":199},"Barbara Ann Karmanos Cancer Institute",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":312,"sex":16,"minAge":208,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":315,"conditions":316,"keywords":317,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":322,"leadSponsor":324,"locationsCount":227},"100132372","collecting-tissue-samples-from-patients-with-cancer-undergoing-radiation-therapy-and-healthy-participants-100132372","NCT00992303","Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants","Tissue Procurement and Outcome Collection for Radiotherapy Treated Patients and Healthy Participants","DISEASE CHARACTERISTICS:\n\n* Pathologically-proven diagnosis of malignancy\n* Planning treatment with radiation therapy\n\nPATIENT CHARACTERISTICS:\n\n* Able to perform follow-up visits\n* Is a patient of the University of Texas Southwestern Medical Center physicians\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Participation in other clinical trials is allowed\n* Other prior or concurrent therapy for cancer, such as surgery and\u002For chemotherapy, is allowed.\n\nCriteria for eligibility:\n\n* Able to provide written informed consent\n* Age greater than 18 years old\n* Males and Females are eligible\n* Any ethnicity is eligible\n\nCriteria for ineligibility:\n\n-Patients not available for follow-up\u002Ffuture contact",true,{"count":314,"type":20},10000,"RATIONALE: Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.\n\nPURPOSE: This research study is collecting tissue samples from patients with cancer undergoing radiation therapy. Healthy participants will also be allowed on the trial so their samples can be used in comparison to patients with malignancy",[32],[35],"2025-05-08",{"date":320,"type":192},"2025-05-14",{"date":194,"type":4},{"date":323,"type":20},"2029-12",{"name":325,"class":199},"University of Texas Southwestern Medical Center"]